A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
Status:
Completed
Trial end date:
2019-07-10
Target enrollment:
Participant gender:
Summary
Evaluation of safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ISIS
416858 for up to 204 participants with ESRD receiving chronic hemodialysis as assessed by FXI
activity reduction.